FUKUSHIMA JOURNAL OF MEDICAL SCIENCE
Online ISSN : 2185-4610
Print ISSN : 0016-2590
ISSN-L : 0016-2590
Vasculitic myopathy as the initial manifestation of microscopic polyangiitis with sustained remission following rituximab induction and avacopan maintenance: a case report
Shuhei Yoshida, So Yamamoto, Jumpei Temmoku, Isamu Higuchi, Kenji Saito, Akihito Utsumi, Yumiko Kuromi, Haruki Matsumoto, Tomoyuki Asano, Shuzo Sato, Yuko Hashimoto, Kazuaki Kanai, Yasuhiro Shimojima
Author information
JOURNAL OPEN ACCESS FULL-TEXT HTML Advance online publication

Article ID: 26-00039

Details
Abstract

Microscopic polyangiitis (MPA), a form of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), can involve skeletal muscle. However, vasculitic myopathy remains underrecognized, and no consensus has been established regarding its optimal management. A 67-year-old Japanese man presented with progressive myalgia predominantly affecting the lower extremities. Laboratory evaluation revealed elevated inflammatory markers and myeloperoxidase-ANCA positivity, while serum creatine kinase levels remained within the normal range. Thigh magnetic resonance imaging (MRI) demonstrated diffuse hyperintensity on short tau inversion recovery sequences involving the quadriceps muscles. Muscle biopsy revealed inflammatory cell infiltration with fibrinoid necrosis in small vessels, confirming the diagnosis of vasculitic myopathy associated with MPA. Remission was achieved with induction therapy using glucocorticoids and rituximab, followed by maintenance therapy with avacopan. Subsequent MRI showed complete resolution of muscular abnormalities, and sustained clinical remission was maintained without relapse. This case demonstrates the utility of MRI for the early detection of MPA-associated vasculitic myopathy and for assessing treatment response, and suggests that avacopan may be a promising option for remission maintenance in this condition.

Content from these authors
© 2026 The Fukushima Society of Medical Science

This article is licensed under a Creative Commons [Attribution-NonCommercial-ShareAlike 4.0 International] license.
https://creativecommons.org/licenses/by-nc-sa/4.0/
Previous article Next article
feedback
Top